For people with dMMR/MSI-H* endometrial cancer that has spread outside the uterus (advanced) or has returnedJEMPERLI in combination with carboplatin and paclitaxel offers a personalized treatment option

*dMMR/MSI-H stands for “mismatch repair deficiency/microsatellite instability-high.” These are important biomarkers in endometrial cancer that can help your doctor decide if JEMPERLI is appropriate for you.

How the effectiveness of JEMPERLI was studied

A clinical trial compared JEMPERLI in combination with carboplatin and paclitaxel versus carboplatin and paclitaxel alone in 122 people with dMMR/MSI-H endometrial cancer that had spread outside the uterus (advanced) or returned.

Four people with light bulbs icon

Study participants taking JEMPERLI in combination with carboplatin and paclitaxel received:

500 mg of JEMPERLI with carboplatin and paclitaxel every 3 weeks for 6 doses

Then 1000 mg of JEMPERLI alone every 6 weeks

Four people icon

Study participants taking carboplatin and paclitaxel alone received:

Carboplatin and paclitaxel with a placebo (an inactive substance designed to look like the medicine being tested) every 3 weeks for 6 doses

Then placebo alone every 6 weeks

How JEMPERLI may help

The JEMPERLI clinical trial measured median progression-free survival (PFS). Median PFS refers to the length of time that half of study participants lived without their cancer spreading, growing, or getting worse. The trial is still ongoing to see if study participants live longer overall with treatment.

Median months without cancer growing, spreading, or getting worse

NEARLY 4X LONGER than carboplatin and paclitaxel alone

Clinical trial results for JEMPERLI taken in combination with carboplatin and paclitaxel

30 months median

8 months median

Study participants receiving JEMPERLI in combination with carboplatin and paclitaxel

Study participants receiving carboplatin and paclitaxel alone

Cancer grew, spread, or got worse for 23 out of 60 study participants treated with JEMPERLI in combination with carboplatin and paclitaxel, compared with 47 out of 62 people treated with carboplatin and paclitaxel alone.

Clinical trial icon

Study participants receiving JEMPERLI in combination with carboplatin and paclitaxel were 71% less likely to have their cancer grow, spread, or get worse compared with people receiving carboplatin and paclitaxel alone.

Most study participants receiving JEMPERLI in combination with carboplatin and paclitaxel had their tumors disappear or partially shrink

Response rates for JEMPERLI in combination with carboplatin and paclitaxel

74% of study participants had tumors DISAPPEAR OR PARTIALLY SHRINK (31 of 42 participants)

26% of study participants had tumors DISAPPEAR (11 of 42 participants)

48% of study participants had tumors PARTIALLY SHRINK (20 of 42 participants)

For the 45 study participants who received carboplatin and paclitaxel alone:

  • 62% had tumors disappear or partially shrink (28 of 45 participants)
    • 11% had tumors disappear (5 of 45 participants)
    • 51% had tumors partially shrink (23 of 45 participants)

This does not always mean that the cancer has been cured.

You are not alone

Endometrial cancer statistics infographic

About 60,000 cases of endometrial cancer are diagnosed annually in the US

About 1 in 4 peoplepeople with endometrial cancer has cancer that has come back after treatment or has spread outside the uterus (advanced cancer)

Light bulb icon

Is JEMPERLI right for you?

If you were diagnosed with dMMR/MSI-H endometrial cancer that has spread outside the uterus (advanced) or your cancer has returned, ask your doctor if JEMPERLI may be right for you.

Learn About dMMR/MSI-H

Light bulb icon

What is JEMPERLI?

JEMPERLI is an immunotherapy. This means it is designed to work with the body’s immune system to help fight cancer.

Learn How It Works

Exclamation point in triangle icon

What are the side effects of JEMPERLI?

Certain side effects have been observed in people taking JEMPERLI. While everyone’s treatment experience is different, knowing what you may expect can help.

See Risks and Side Effects

Download icon

Resources for you

Knowledge is power. That's why we're committed to providing you with educational resources to help you stay informed along your treatment journey.

Go to Resources

Related FAQs

  • How many people participated in the clinical trial of JEMPERLI in combination with carboplatin and paclitaxel?

    The clinical trial that studied the effectiveness of JEMPERLI in combination with the chemotherapy medicines, carboplatin and paclitaxel, included 122 people. They had dMMR/MSI-H endometrial cancer that had spread outside the uterus (advanced) or had returned.

    The clinical trial also studied the risks and side effects of JEMPERLI in combination with the chemotherapy medicines, carboplatin and paclitaxel, in 52 people with advanced or returned dMMR/MSI-H endometrial cancer.

  • What is a biomarker?

    A biomarker (BY-oh-MAR-ker) is a molecule found in the tissues or fluids of your body that shows if a condition, process, or disease is normal or abnormal. Endometrial cancer may have a biomarker known as dMMR (mismatch repair deficiency). Testing for this biomarker can help your doctor decide if JEMPERLI is right for you.